Atomoxetine in the treatment of attention deficit hyperactivity disorder

Christopher J. Kratochvil, Brigette S. Vaughan, Joan M. Daughton, Michelle L. Mayfield-Jorgensen, William J. Burke

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Atomoxetine (Strattera™ Eli Lilly & Co.) is a highly selective noradrenaline reuptake inhibitor and the first nonstimulant medication to be approved for the treatment of attention deficit hyperactivity disorder. Currently, nine published clinical trials have documented the safety and efficacy of atomoxetine in the treatment of children, adolescents and adults with attention deficit hyperactivity disorder and data presented throughout the past year at national scientific meetings has further addressed its utility. This article reviews the available information on atomoxetine, accompanied by a discussion of its clinical use.

Original languageEnglish (US)
Pages (from-to)601-611
Number of pages11
JournalExpert Review of Neurotherapeutics
Issue number4
StatePublished - Jul 2004


  • Atomoxetine
  • Attention deficit hyperactivity disorder
  • Norepinephrine
  • Psychopharmacology

ASJC Scopus subject areas

  • General Neuroscience
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Atomoxetine in the treatment of attention deficit hyperactivity disorder'. Together they form a unique fingerprint.

Cite this